Is there a role for XXXX after shock wave lithotripsy in the treatment of renal and ureteral calculi?

@entity1 @entity9940
INTRODUCTION: Our study aimed at defining the role of @entity9940 as adjunctive therapy after extracorporeal shock wave lithotripsy (ESWL) in @entity1 with stones in the kidney and ureter. MATERIALS AND METHODS: A placebo-controlled, randomized, double-blind clinical trial prospectively performed between February 2008 and September 2009 on 150 @entity1 with 4-20 mm in diameter renal and ureteral stones referred to our ESWL center. After ESWL, all @entity1 randomly assigned to two groups (placebo and @entity9940 ). The drugs administration was started immediately after ESWL and was continued for a maximum of 30 days. RESULTS: From 150 @entity1 , 71 in control group and 70 in case group completed the study. Of 71 @entity1 (60.56%) in control group, 43 @entity1 became stone free; and other @entity1 (39.44%) did not succeed in stone expulsion during 12 weeks after ESWL. In case group of 70 @entity1 (71.4%), 50 @entity1 became stone free. Time of stone passage in most of the @entity1 happened between 20th and 30th day in control group (32.6%) and between 10th and 20th day (50%) in case group after ESWL. There is no statistically significant difference between stone passage in two groups (p = 0.116) and location of stone (p = 0.114), but there is statistically significant difference in time of stone passage from onset of treatment in case and control groups (p = 0.002). CONCLUSION: At last, this study suggested that @entity9940 facilitate earlier clearance of fragments after ESWL.
